Physician profile
Ruchi Patel
NPI 1619317229
$6,815.36
in general payments reported to CMS, 2019-2025
30 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.49 · 2020: $793 · 2021: $104 · 2022: $754 · 2023: $2,766 · 2024: $1,939 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,058 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.04 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,177.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,100.65 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $745.16 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Olympus Corporation of The Americas | $642.72 | 2020 | |
| Celgene Corporation | $636.15 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.21 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Lilly USA, LLC | $289.89 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $208.61 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $171.84 | 2022-2025 | Linzess |
| Genzyme Corporation | $154.16 | 2023-2025 | |
| Gilead Sciences, INC. | $151.66 | 2020-2023 | |
| Janssen Scientific Affairs, LLC | $132.50 | 2022-2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $113.63 | 2024 | Iqirvo |
| Qol Medical, LLC | $94.07 | 2023-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $92.30 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $90.98 | 2023 | Ibsrela |
| Boston Scientific Corporation | $89.67 | 2021 | |
| Intercept Pharmaceuticals, INC. | $81.67 | 2023-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $74.28 | 2024 | Dificid |
| Vivus LLC | $64.13 | 2023-2024 | Pancreaze |
| Pfizer INC. | $50.88 | 2022 | |
| Braintree Laboratories, INC. | $45.96 | 2022-2023 | Sutab |
| Evoke Pharma, INC. | $44.42 | 2023-2025 | Gimoti |
| Ferring Pharmaceuticals INC. | $44.22 | 2023 | Clenpiq, Rebyota |
| Abiomed | $40.91 | 2025 | |
| Medtronic, INC. | $33.26 | 2023 | Endoflip |
| Madrigal Pharmaceuticals | $26.51 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $23.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.50 | 2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $19.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.